NCT07472647 2026-03-16
SYS6090 Combination Therapy in Advanced Lung Cancer
Shanghai JMT-Bio Inc.
Phase 1/2 Not yet recruiting
Clinical Trials
11 trialsNCT07453394 2026-03-06
QLS5132 Combination Therapy in Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT07288034 2025-12-17
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT07244926 2025-11-24
Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07134413 2025-08-21
QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC
Guangdong Association of Clinical Trials
Phase 2 Not yet recruiting
NCT07083375 2025-07-24
QL1706
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT07001618 2025-07-23
IMMUNOLIFE2
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Not yet recruiting
NCT07014215 2025-06-10
PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy
Anhui Provincial Cancer Hospital
Phase 2 Not yet recruiting
NCT06683703 2024-11-12
Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 2 Not yet recruiting
NCT06537297 2024-09-20
Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases
Hunan Province Tumor Hospital
Phase 2 Not yet recruiting
NCT06557096 2024-08-16
CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC
Second Affiliated Hospital of Nanchang University
Phase EARLY_PHASE1 Not yet recruiting